Table 2.
Serum and urine measurements of minerals and intact parathormone (iPTH) at baseline (T0) and after intervention (T1). Quantitative variables with a normal distribution are expressed as mean ± SD; quantitative variables which showed a non-normal distribution are expressed as median (P25–P75).
| T0 | T1 | |||||||
|---|---|---|---|---|---|---|---|---|
| Placebo Group | Synergy 1 Group | p-Value | Placebo Group | Synergy 1 Group | p-Value |
p-Value Placebo T0 vs. T1 |
p-Value Synergy 1 T0 vs. T1 |
|
| Serum | ||||||||
| Ca [mg/dL] | 9.4 ± 0.3 | 9.2 ± 0.3 | 0.179 | 9.2 ± 0.3 | 9.3 ± 0.2 | 0.552 | 0.450 | 0.249 |
| P [mg/dL] | 4.7 (4.3–5.2) | 4.5 (4.2–4.9) | 0.469 | 4.8 (4.6–5.0) | 4.6 (4.3–5.0) | 0.250 | 0.169 | 0.932 |
| Mg [mg/dL] | 2.0 (1.9–2.2) | 2.1 (2.0–2.2) | 0.479 | 1.9 (1.9–2.1) | 2.1 (2.0–2.1) | 0.336 | 0.959 | 0.727 |
| Total protein [g/dL] | 7.5 (7.1–7.6) | 7.4 (7.1–7.6) | 0.843 | 7.1 (6.9–7.3) a | 7.2 ± 0.4 | 0.174 | 0.008 | 0.103 |
| Albumin [g/dL] | 4.2 (4.0–4.3) | 4.2 (4.0–4.3) | 0.809 | 4.1 (4.0–4.1) a | 4.2 (4.0–4.3) | 0.357 | 0.041 | 0.307 |
| Plasma | ||||||||
| iPTH [pg/mL] | 20.9 (12.0–33.4) | 22.5 (15.6–31.1) | 0.931 | 22.7 (12.7–30.1) | 23.9 (14.4–29.0) | 0.688 | 0.875 | 0.528 |
| Urine | ||||||||
| Ca [mg/mg Cr *] | 0.07 (0.05–0.27) | 0.09 (0.03–0.08) | 0.605 | 0.08 (0.05–0.11) | 0.09 (0.03–0.08) | 0.890 | 0.593 | 0.925 |
| P [mg/mg Cr] | 0.85 ± 0.34 | 0.90 ± 0.41 | 0.448 | 1.06 ± 0.37 a | 0.90 ± 0.41 | 0.297 | 0.046 | 0.058 |
| Mg [mg/mg Cr] | 0.15 ± 0.06 | 0.15 ± 0.05 | 0.443 | 0.15 ± 0.07 | 0.15 ± 0.05 | 0.948 | 0.575 | 0.634 |
* Cr—creatinine. a —statistically significant differences within groups before and after intervention (p < 0.05).